AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 1 - 30 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories: ?Isolated bone marrow relapse ?Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse. 2) Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes.

You may not be eligible for this study if the following are true:

  • 1) Patients with B-lymphoblastic lymphoma (B-LLy). 2) Patients with Burkitt Leukemia/Lymphoma or mature B-cell leukemia. 3) Patients with Philadelphia chromosome positive (Ph+) B-ALL. 4) Patients with mixed phenotype acute leukemia (MPAL).

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.